melanoma

Researchers used the system to improve a method for analyzing lymph nodes and believe it could improve the care of patients with these and other early-stage cancers.

The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.

In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.

Researchers have shown nanoparticles can enrich low molecular weight, low abundance plasma proteins that are hard to detect using standard proteomic workflows.

A handful of exposures to ultraviolet radiation was enough to induce the melanoma-associated signature within a mouse model.

This Week in PLOS

In PLOS this week: nucleosome structure linked to UV-induced melanoma mutational signatures, genetic diversity and population structure in reindeer, and more.

Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.

Palmetto GBA issued final local coverage determination for the tissue-based, 31-gene expression test, which determines a patient’s risk for metastatic disease.  

A Rutgers University cancer researcher says she was fired in retaliation for challenging an authorship decision, ScienceInsider reports.

The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.